Asked by: Sarah Pochin (Reform UK - Runcorn and Helsby)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what assessment her Department has made of the potential merits of providing limited amounts of non-mRNA COVID-19 vaccines available for patients with clinical contraindications to mRNA vaccines, including through the importation of products already authorised by trusted international regulators.
Answered by Ashley Dalton - Parliamentary Under-Secretary (Department of Health and Social Care)
The Government is committed to protecting those most vulnerable to COVID-19 through vaccination, as guided by the independent Joint Committee on Vaccination and Immunisation (JCVI). The primary aim of the national COVID-19 vaccination programme remains the prevention of serious illness, resulting in hospitalisations and deaths, arising from COVID-19.
The Government has accepted the JCVI’s advice for autumn 2025 and in line with the advice, a COVID-19 vaccination is being offered to the following groups:
As for all vaccines, the JCVI keeps all vaccination programmes under review.
COVID-19 vaccines are procured by the UK Health Security Agency (UKHSA) in line with JCVI advice.
UKHSA advise that as with all vaccines there will be an extremely small proportion of people who cannot receive a particular COVID-19 vaccine due to an anaphylactic reaction, this includes mRNA vaccines. Advice published in the UKHSA Green Book recommends that anyone with a prior allergic reaction to COVID-19 vaccines should be seen by an expert allergist and, after a review of the individual’s risks and benefits of vaccination, where it is indicated, they could then be vaccinated in hospital under clinical supervision. Information is not held centrally on how many people seen under this pathway are unable to receive an mRNA COVID-19 vaccine even in a hospital setting. Where an allergist has advised that a vaccine is not suitable, and this is the only type of vaccine available in a particular campaign, the individual should be advised of other mitigations to reduce their risk of becoming infected and be provided with information on access to treatments should they test positive for infection.
Asked by: Sarah Pochin (Reform UK - Runcorn and Helsby)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what assessment his Department has made of the potential merits of establishing a national referral pathway or specialist hub for people who cannot receive mRNA vaccines to ensure equitable access to appropriate COVID-19 vaccinations.
Answered by Ashley Dalton - Parliamentary Under-Secretary (Department of Health and Social Care)
The Government is committed to protecting those most vulnerable to COVID-19 through vaccination, as guided by the independent Joint Committee on Vaccination and Immunisation (JCVI). The primary aim of the national COVID-19 vaccination programme remains the prevention of serious illness, resulting in hospitalisations and deaths, arising from COVID-19.
The Government has accepted the JCVI’s advice for autumn 2025 and in line with the advice, a COVID-19 vaccination is being offered to the following groups:
As for all vaccines, the JCVI keeps all vaccination programmes under review.
COVID-19 vaccines are procured by the UK Health Security Agency (UKHSA) in line with JCVI advice.
UKHSA advise that as with all vaccines there will be an extremely small proportion of people who cannot receive a particular COVID-19 vaccine due to an anaphylactic reaction, this includes mRNA vaccines. Advice published in the UKHSA Green Book recommends that anyone with a prior allergic reaction to COVID-19 vaccines should be seen by an expert allergist and, after a review of the individual’s risks and benefits of vaccination, where it is indicated, they could then be vaccinated in hospital under clinical supervision. Information is not held centrally on how many people seen under this pathway are unable to receive an mRNA COVID-19 vaccine even in a hospital setting. Where an allergist has advised that a vaccine is not suitable, and this is the only type of vaccine available in a particular campaign, the individual should be advised of other mitigations to reduce their risk of becoming infected and be provided with information on access to treatments should they test positive for infection.
Asked by: Sarah Pochin (Reform UK - Runcorn and Helsby)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, how many people are clinically unable to receive mRNA-based COVID-19 vaccines; and how this figure has been derived.
Answered by Ashley Dalton - Parliamentary Under-Secretary (Department of Health and Social Care)
The Government is committed to protecting those most vulnerable to COVID-19 through vaccination, as guided by the independent Joint Committee on Vaccination and Immunisation (JCVI). The primary aim of the national COVID-19 vaccination programme remains the prevention of serious illness, resulting in hospitalisations and deaths, arising from COVID-19.
The Government has accepted the JCVI’s advice for autumn 2025 and in line with the advice, a COVID-19 vaccination is being offered to the following groups:
As for all vaccines, the JCVI keeps all vaccination programmes under review.
COVID-19 vaccines are procured by the UK Health Security Agency (UKHSA) in line with JCVI advice.
UKHSA advise that as with all vaccines there will be an extremely small proportion of people who cannot receive a particular COVID-19 vaccine due to an anaphylactic reaction, this includes mRNA vaccines. Advice published in the UKHSA Green Book recommends that anyone with a prior allergic reaction to COVID-19 vaccines should be seen by an expert allergist and, after a review of the individual’s risks and benefits of vaccination, where it is indicated, they could then be vaccinated in hospital under clinical supervision. Information is not held centrally on how many people seen under this pathway are unable to receive an mRNA COVID-19 vaccine even in a hospital setting. Where an allergist has advised that a vaccine is not suitable, and this is the only type of vaccine available in a particular campaign, the individual should be advised of other mitigations to reduce their risk of becoming infected and be provided with information on access to treatments should they test positive for infection.
Asked by: Helen Maguire (Liberal Democrat - Epsom and Ewell)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what steps his Department is taking to decrease treatment wait times for patients with metastatic ocular melanoma.
Answered by Ashley Dalton - Parliamentary Under-Secretary (Department of Health and Social Care)
The Department remains committed to ensuring that cancer patients, including those with metastatic ocular melanoma, have timely access to treatment and tailored medical support.
The Government supports Scott Arthur’s Private Members Bill on rare cancers which will make it easier for clinical trials into rare cancers to take place in England by ensuring the patient population can be easily contacted by researchers. This will ensure that the National Health Service will remain at the forefront of medical innovation and is able to provide patients with the newest, most effective treatment options, and ultimately boost survival rates.
The forthcoming National Cancer Plan will include further details on how we will improve outcomes for patients with cancer, as well as speeding up diagnosis and treatment, ensuring patients have access to the latest treatments and technology, and ultimately driving up this country’s cancer survival rates. This will benefit all cancer patients, including metastatic ocular melanoma patients.
Asked by: Lee Dillon (Liberal Democrat - Newbury)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what steps he is taking with Cabinet colleagues to help tackle health disparities amongst people who live in the most deprived areas.
Answered by Ashley Dalton - Parliamentary Under-Secretary (Department of Health and Social Care)
It is a priority for the Government is to increase the amount of time people spend in good health and prevent premature deaths, with a vision of ensuring that all individuals, regardless of background or location, live longer, healthier lives.
Our 10-Year Health Plan for the National Health Service in England sets out a reimagined service designed to tackle inequalities in both access and outcomes, as well as to give everyone, no matter who they are or where they come from, the means to engage with it on their own terms. Delivering the plan is a cross-Government effort.
For example, we know that the Carr-Hill formula is considered outdated, and evidence suggests that general practices (GPs) serving in deprived parts of England receive on average 9.8% less funding per needs-adjusted patient than those in less deprived communities, despite having greater health needs and significantly higher patient-to-GP ratios. This is why we are currently reviewing the formula to ensure that resources are targeted where they are most needed.
We also recognise that much of what determines of health and wellbeing in influenced by factors other than health services. Recent cross-Government action has included the introduction of Awaab’s Law and reform of the Decent Homes Standard for the social and private rented sector, the English Devolution Bill, and a new statutory heath inequalities duty for strategic authorities.
Asked by: Al Pinkerton (Liberal Democrat - Surrey Heath)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what steps he is taking with the Secretary of State for Health and Social Care to help tackle health inequalities affecting women in Surrey.
Answered by Ashley Dalton - Parliamentary Under-Secretary (Department of Health and Social Care)
The Government is committed to building a fairer Britain, to ensure people can live well for longer. Our reimagined National Health Service will tackle inequalities in both access and outcomes, as well as give women, no matter who they are or where they come from, the means to engage with the NHS on their own terms.
This financial year the Department has invested approximately £53 million in direct awards on research to support the health of women. This includes conditions that are unique to women, such as endometriosis, and health topics that are relevant to women such as violence and abuse.
Significant progress has been made towards delivering the ambitions in the 2022 Women’s Health Strategy, for example improving women and girls’ awareness and access to services as well as driving research to benefit women’s health, but we know there is more to do.
That is why we are renewing the Women’s Health Strategy, to assess the progress that has been made so far and to continue progressing delivery.
The renewed strategy will update on the delivery of the 2022 Women’s Health Strategy and set out how the Government is taking further steps to improve women’s health as we deliver the 10-Year Health Plan. It will also address gaps from the 2022 strategy and drive further change on enduring challenges such as creating a system that listens to women and tackling health inequalities.
Asked by: Bob Blackman (Conservative - Harrow East)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what learning has been implemented following the coroner’s finding that harm from sodium valproate exposure contributed to the death of Jake Aldcroft.
Answered by Zubir Ahmed - Parliamentary Under-Secretary (Department of Health and Social Care)
Everyone who has been harmed from sodium valproate has our deepest sympathies.
Action has been taken to minimise the risk of foetal harm associated with valproate, and to ensure that healthcare professionals are also able to support any babies and families that are affected. The valproate Pregnancy Prevention Programme ensures that women and girls taking valproate understand the potential risks should they become pregnant, are using effective contraception, and are regularly monitored. It is supported by educational materials for healthcare professionals and patients.
The programme was updated in January 2024 to reflect updated Medicines and Healthcare Products Regulatory Agency advice that valproate must not be started in new patients, either male or female, younger than 55 years old, unless two specialists independently consider and document that there is no other effective or tolerated treatment, or there are compelling reasons that the reproductive risks do not apply.
Asked by: James McMurdock (Independent - South Basildon and East Thurrock)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, with reference to the press release entitled Faster treatments and support for health workers as AI tackles A&E bottlenecks, published on 28 December 2025, if he will commission an independent evaluation of the potential impact of AI‑enabled A&E systems on NHS organisations utilising them.
Answered by Zubir Ahmed - Parliamentary Under-Secretary (Department of Health and Social Care)
Currently, there are no plans for a formal independent evaluation of the potential impact of artificial intelligence (AI) enabled accident and emergency systems on National Health Service organisations. However, NHS England is undertaking an internal evaluation, as the particular AI tool referenced within the press release is an NHS England development, built within the Federated Data Platform.
The tool has been subject to quality assurance and includes built-in metrics to monitor forecast accuracy and performance over time. To date, evaluation has focused on technical robustness, data quality, and usability, rather than the direct impacts on waiting times, which are influenced by multiple factors beyond demand forecasting alone.
Asked by: Helen Maguire (Liberal Democrat - Epsom and Ewell)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what assessment has been made of the merits of providing training to mental health teams to support children with lifelong speech and language difficulties.
Answered by Zubir Ahmed - Parliamentary Under-Secretary (Department of Health and Social Care)
No such specific assessment has been made. The Department of Health and Social Care is working closely with the Department for Education and NHS England to improve access to community health services, including speech and language therapy, for children and young people with special educational needs and disabilities.
In addition to the undergraduate degree route, speech and language therapists can now also train via a degree apprenticeship. This route is going into its fourth year of delivery and offers an alternative pathway to the traditional degree route into a successful career as a speech and language therapist.
In partnership with NHS England, the Department for Education has extended the Early Language and Support for Every Child programme, trialling new ways of working to better identify and support children with Speech, Language and Communication Needs in early years settings and primary schools.
Asked by: Bob Blackman (Conservative - Harrow East)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what assessment has been made of the adequacy of the diagnostic time taken and levels of misdiagnosis among individuals harmed by sodium valproate, and its impact on long-term outcomes.
Answered by Zubir Ahmed - Parliamentary Under-Secretary (Department of Health and Social Care)
The Independent Medicines and Medical Devices Safety Review, First Do No Harm, identified significant shortcomings in National Health Service care pathways for people harmed by sodium valproate, including fragmented services, limited diagnostic expertise, delays in diagnosis, and inequitable access to multidisciplinary care. NHS England has acknowledged variation in the availability and adequacy of care pathways, the impact of delayed diagnosis and misdiagnosis on long-term outcomes, and the need for improved care coordination for those requiring lifelong support.
In response, NHS England has commissioned a Fetal Exposure to Medicines Services Pilot, being delivered by the Newcastle upon Tyne Hospitals NHS Foundation Trust and the Manchester University NHS Foundation Trust. The pilot provides multidisciplinary diagnostic assessment and is informing the development of improved care pathways, including consideration of specialist multidisciplinary services to support earlier diagnosis, better coordination of care, and reduced reliance on emergency care. Initial learning was shared with NHS England in September 2025, with final recommendations expected this summer to inform decisions on any national commissioning, subject to funding.
Finally, whilst integrated care boards (ICBs) are the responsible commissioners of the majority of health services, including services related to medically induced disabilities, no specific guidance has been issued to ICBs in relation to supporting individuals with complex, medicine-induced disabilities arising from sodium valproate.